KPIs & Operating Metrics(New)
Growth Metrics

AbbVie (ABBV) Interest & Investment Income (2012 - 2026)

AbbVie (ABBV) reported Interest & Investment Income of -$645.0 million for Q1 2026, down 2.87% year-over-year from -$664.1 million in Q1 2025, and up 1.53% on a QoQ basis from -$655.0 million in Q4 2025.

AbbVie (ABBV) has 15 years of Interest & Investment Income data on file, last reported at -$645.0 million in Q1 2026.

  • Quarterly Interest & Investment Income fell 2.87% year-over-year to -$645.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$2.6 billion (down 13.32% YoY) and the FY2025 annual result came in at -$2.6 billion, down 21.62% from the prior year.
  • Interest & Investment Income climbed to -$645.0 million in Q1 2026 per ABBV's latest filing, from -$655.0 million in the prior quarter.
  • Across five years, Interest & Investment Income topped out at -$378.0 million in Q4 2023 and bottomed at -$678.0 million in Q2 2025.
  • The 5-year median for Interest & Investment Income is -$532.0 million (2022), against an average of -$538.8 million.
  • The widest annual swing landed in 2023, when Interest & Investment Income increased 20.59%; it then plunged 61.38% in 2024.
  • Tracing ABBV's Interest & Investment Income over 5 years: stood at -$476.0 million in 2022, then advanced by 20.59% to -$378.0 million in 2023, then sank by 61.38% to -$610.0 million in 2024, then slipped by 7.38% to -$655.0 million in 2025, then grew by 1.53% to -$645.0 million in 2026.
  • Per Business Quant, the three latest ABBV Interest & Investment Income figures stand at -$645.0 million (Q1 2026), -$655.0 million (Q4 2025), and -$667.0 million (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Int & Inv Inc (Qtr)
1 Novartis Ag 107,124,802.25 Bn 107,124,802.25 Bn - -
2 Eli Lilly 969.00 Bn 963.72 Bn 16.22 Bn -
3 Johnson & Johnson 539.46 Bn 517.41 Bn 15.96 Bn 229.00 Mn
4 AbbVie 376.92 Bn 367.57 Bn 10.78 Bn -645.00 Mn
5 Merck 285.00 Bn 279.35 Bn 12.09 Bn -
6 Amgen 177.58 Bn 165.55 Bn 5.87 Bn -
7 Gilead Sciences 163.22 Bn 155.50 Bn 5.52 Bn -
8 Pfizer 145.86 Bn 133.09 Bn -1.21 Bn -
9 Bristol Myers Squibb 111.90 Bn 101.44 Bn 8.07 Bn -
10 Gsk 88.34 Bn 83.66 Bn - -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 -645.00 Mn
Dec 31, 2025 -655.00 Mn
Sep 30, 2025 -667.00 Mn
Jun 30, 2025 -678.00 Mn
Mar 31, 2025 -627.00 Mn
Dec 31, 2024 -610.00 Mn
Sep 30, 2024 -591.00 Mn
Jun 30, 2024 -506.00 Mn
Mar 31, 2024 -453.00 Mn
Dec 31, 2023 -378.00 Mn
Sep 30, 2023 -398.00 Mn
Jun 30, 2023 -454.00 Mn
Mar 31, 2023 -454.00 Mn
Dec 31, 2022 -476.00 Mn
Sep 30, 2022 -497.00 Mn
Jun 30, 2022 -532.00 Mn
Mar 31, 2022 -539.00 Mn
Dec 31, 2021 -571.00 Mn
Sep 30, 2021 -585.00 Mn
Jun 30, 2021 -606.00 Mn
Mar 31, 2021 -622.00 Mn
Dec 31, 2020 -618.00 Mn
Sep 30, 2020 -620.00 Mn
Jun 30, 2020 -614.00 Mn
Mar 31, 2020 -428.00 Mn
Dec 31, 2019 -455.00 Mn
Sep 30, 2019 -420.00 Mn
Jun 30, 2019 -309.00 Mn
Mar 31, 2019 -325.00 Mn
Dec 31, 2018 -319.00 Mn
Sep 30, 2018 -302.00 Mn
Jun 30, 2018 -272.00 Mn
Mar 31, 2018 -251.00 Mn
Dec 31, 2017 -252.00 Mn
Sep 30, 2017 -252.00 Mn
Jun 30, 2017 -253.00 Mn
Mar 31, 2017 -247.00 Mn
Dec 31, 2016 -290.00 Mn
Sep 30, 2016 -250.00 Mn
Jun 30, 2016 -225.00 Mn
Mar 31, 2016 -200.00 Mn
Dec 31, 2015 -199.00 Mn
Sep 30, 2015 -197.00 Mn
Jun 30, 2015 -164.00 Mn
Mar 31, 2015 -126.00 Mn
Dec 31, 2014 -419.00 Mn
Sep 30, 2014 -128.00 Mn
Jun 30, 2014 -69.00 Mn
Mar 31, 2014 5.00 Mn
Dec 31, 2013 -68.00 Mn
Sep 30, 2013 -69.00 Mn
Jun 30, 2013 -75.00 Mn
Mar 31, 2013 -66.00 Mn
Dec 31, 2012 6.00 Mn
Sep 30, 2012 11.00 Mn
Jun 30, 2012 2.00 Mn
Mar 31, 2012 1.00 Mn